Generic Ilevro Availability
ILEVRO (nepafenac - suspension/drops;ophthalmic)
Manufacturer: NOVARTIS PHARMS CORP
Approval date: October 16, 2012
Strength(s): 0.3% [RLD]
Has a generic version of Ilevro been approved?
No. There is currently no therapeutically equivalent version of Ilevro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ilevro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Ophthalmic compositions containing galactomannan polymers and borate
Issued: June 11, 2002
Inventor(s): Bahram; Asgharian
Assignee(s): Alcon Manufacturing, Ltd.
The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions of the eye.Patent expiration dates:
- July 17, 2018✓
- July 17, 2018
Ophthalmic compositions containing a synergistic combination of two polymers
Issued: May 24, 2011
Inventor(s): Chowhan; Masood A. & Chen; Huagang
Assignee(s): Alcon, Inc.
Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.Patent expiration dates:
- June 8, 2024✓
- June 8, 2024
Carboxyvinyl polymer-containing nanoparticle suspensions
Issued: December 30, 2014
Assignee(s): Alcon Research, Ltd.
The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.Patent expiration dates:
- March 31, 2032✓
- March 31, 2032
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 16, 2015 - NEW PRODUCT
More about Ilevro (nepafenac ophthalmic)
- Other brands: Nevanac
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|